Product
GS-9911
1 clinical trial
1 indication
Indication
Solid TumorsClinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-01